Selecta Biosciences Stock News

WATERTOWN, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic ther

WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic ther

Results for both studies from the DISSOLVE phase 3 program, using SEL-212 for the treatment of patients with chronic refractory gout, are expected in Q1 of 2023. Potential to restore immune tolerance

Selecta Biosciences, Inc. (NASDAQ:SELB ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Kevin Tan – Chief Financial Officer Carsten Brunn – President and Chief Exe

WATERTOWN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic thera

Selecta Biosciences, Inc. (SELB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near te

SVB Leerink initiated Selecta Biosciences Inc (NASDAQ: SELB) coverage with an Outperform rating and a price target of $7. The analysts view ImmTOR's approach to mitigate ADAs as de-risked by early

These biotech stocks are speculative, but could potentially blow up in the next couple of years with new treatments in the pipelines. The post 7 Cheap Biotech Stocks to Buy Now appeared first on Inves

WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therap

Selecta Biosciences, Inc. (NASDAQ:SELB ) Q1 2021 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Carsten Brunn - President & Chief Executive Officer Kevin Tan - Chief Financial Of

WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic ther

During the last session, Selecta Biosciences Inc. (NASDAQ:SELB)’s traded shares were 0.75 million, with the beta value of the company hitting 1.24. At the end of the trading day, the stock’s price was $1.65, reflecting an intraday loss of -5.71% or -$0.1. The 52-week high for the SELB share is $5.28, that puts it down … Selecta Biosciences Inc. (NASDAQ: SELB) Rose 10.3% From Its 52-Week Low; YTD Numbers Fall -49.39% – Here Are Some Things To Keep In Mind Read More »

Selecta Biosciences (SELB) CEO Carsten Brunn on Q4 2021 Results - Earnings Call Transcript

Selecta Biosciences press release (SELB): Q4 GAAP EPS of $0.10 beats by $0.18.Revenue of $29.9M (+150.2% Y/Y) beats by $12.32M.Selecta had $129.4 million in cash, cash…